J
John Q. Trojanowski
Researcher at University of Pennsylvania
Publications - 1538
Citations - 245534
John Q. Trojanowski is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Dementia & Alzheimer's disease. The author has an hindex of 226, co-authored 1467 publications receiving 213948 citations. Previous affiliations of John Q. Trojanowski include Vanderbilt University & University of California, San Francisco.
Papers
More filters
Journal ArticleDOI
Malignant tumors of nerve sheath origin
TL;DR: Criteria were developed for establishing the nerve sheath origin and malignancy of a given neoplasm which allowed a secure diagnosis of malignant nerve she Heath tumor to be made in 11 of the 24 cases, and 7 cases were of uncertain histogenesis.
Journal ArticleDOI
Chronic traumatic encephalopathy is a common co-morbidity, but less frequent primary dementia in former soccer and rugby players
Edward B. Lee,Kevin Kinch,Victoria E. Johnson,John Q. Trojanowski,Douglas H. Smith,William Stewart +5 more
TL;DR: It is suggested that while CTE-NC might be common in former athletes with dementia, in many cases its clinical significance remains uncertain and this consecutive autopsy series identifies neuropathologic change consistent with preliminary diagnostic criteria for CTE (CTE-NC).
Journal ArticleDOI
Survival Profiles of Patients With Frontotemporal Dementia and Motor Neuron Disease
William T. Hu,William T. Hu,Harro Seelaar,Keith A. Josephs,David S. Knopman,Bradley F. Boeve,Eric J. Sorenson,Leo McCluskey,Lauren Elman,Helenius J. Schelhaas,Joseph E. Parisi,Benno Kuesters,Virginia M.-Y. Lee,John Q. Trojanowski,Ronald C. Petersen,John C. van Swieten,Murray Grossman +16 more
TL;DR: Distinct patterns of survival profiles exist in patients with frontotemporal dementia and motor neuron disease, and overall survival may depend on the relative timing of the emergence of secondary symptoms.
Journal ArticleDOI
Microtubule-stabilizing agents as potential therapeutics for neurodegenerative disease.
TL;DR: The growing evidence that small molecule MT-stabilizing agents provide benefit in animal models of neurodegenerative disease is highlighted and the desired features of such molecules for the treatment of these central nervous system disorders are discussed.
Journal ArticleDOI
Neuron-specific age-related decreases in dopamine receptor subtype mRNAs.
TL;DR: The hypothesis that alterations in dopaminergic function may also be related to behavioral abnormalities, such as psychosis, that occur with aging is supported, and senescence may be a factor responsible for cell‐specific decrements in dopamine receptor gene expression in one population of neurons within a circuit that is critical for learning and memory.